Nehal Mohamed - Concepedia

Author

Nehal Mohamed

National University Cancer Institute, Singapore

Also Known As

N Mohamed, Nehal E. Mohamed, Nehal Essam Eldin Mohamed, Nehal Mohamed, Noha refaat Mohamed

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

National University Cancer Institute, Singapore Elusys Therapeutics (United States)Hôpital Claude Huriez Institut Català d'Oncologia Royal Prince Alfred Hospital

About

Nehal Mohamed is an author at National University Cancer Institute, Singapore specializing in medicine, immunology, and infection control.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	1.4K
2	Health Sciences	4	4	946
3	Engineering	2	2	127
4	Natural Sciences	1	1	54
5	Biochemistry	1	1	54

Nehal Mohamed

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study Meletios Α. Dimopoulos, Philippe Moreau, Antonio Palumbo, The Lancet Oncology Hematological MalignancyOncologyDexamethasone Versus BortezomibHematologyMyeloid Neoplasia	2015	834
A High-Affinity Monoclonal Antibody to Anthrax Protective Antigen Passively Protects Rabbits before and after Aerosolized <i>Bacillus anthracis</i> Spore Challenge Nehal Mohamed, Michelle Clagett, Juan Li, Infection and Immunity Veterinary VaccineImmunologyBiological TherapyImmunotherapyBacterial Pathogens	2005	123
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study Philippe Moreau, D. Joshua, W-J Chng, Leukemia Hematological MalignancyRelapsed Multiple MyelomaMedicineHematologyClinical Trials	2016	76
Novel experimental study of receptor-mediated bacterial adhesion under the influence of fluid shear Nehal Mohamed, Thomas R. Rainier, Julia Ross Biotechnology and Bioengineering Tissue EngineeringEngineeringCell AdhesionBacteriologyNovel Experimental Study	2000	69
Enhancement of Anthrax Lethal Toxin Cytotoxicity: a Subset of Monoclonal Antibodies against Protective Antigen Increases Lethal Toxin-Mediated Killing of Murine Macrophages Nehal Mohamed, Juan Li, Cláudia S. Ferreira, Infection and Immunity InflammationImmunotoxicologyMicrobial PathogensAnthrax PaAnthrax Exotoxins	2004	62
Inhibition of<i>Staphylococcus aureus</i>Adherence to Collagen under Dynamic Conditions Nehal Mohamed, Mark Teeters, Joseph M. Patti, Infection and Immunity EngineeringBiomimetic MaterialsCell AdhesionImmunologyBacterial Pathogens	1999	58
Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR W-J Chng, Hartmut Goldschmidt, Meletios Α. Dimopoulos, Leukemia	2016	58
Identification of new potent phthalazine derivatives with VEGFR-2 and EGFR kinase inhibitory activity Kamilia M. Amin, Flora F. Barsoum, Fadi M. Awadallah, European Journal of Medicinal Chemistry Medicinal ChemistryPharmaceutical ScienceDerivative (Chemistry)BiochemistryMedicine	2016	54
Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866) Stuart D. Russell, Alexander R. Lyon, Daniel J. Lenihan, Blood	2015	36
A Phase III, Randomized, Open-Label Study (CONTACT-02) of Cabozantinib Plus Atezolizumab Versus Second Novel Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Neeraj Agarwal, Arun Azad, Joan Carles, Future Oncology	2022	36

Page 1